Subexome panels of cancer predisposing genes in combination with pathogenicity assessment of variants offered a good yield in reclassification, unmasking the limitations of IHC testing and the difficulty of detecting cryptic MMR mutations. The gene discussed is MRC1; the disease is cancer.